Tracker › Companies › Theravance Biopharma, Inc.
3 No sign of it. We found no public evidence tying Theravance Biopharma, Inc.'s cuts to AI.
Every tracked 2026 layoff at Theravance Biopharma, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 3/100 (Minimal) · 80% interval 2–3 · evidence grade D · US · Pharma / Chemicals
Stated reason: On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash …
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · typical Health Care & Pharma roles (no roles named)
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 3,800 workers
Health Care & Pharma · 648 workers
Health Care & Pharma · 419 workers
Health Care & Pharma · 365 workers
Health Care & Pharma · 300 workers
Health Care & Pharma · 120 workers
